Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- 10 February 2006
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (5) , 823-834
Abstract
This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.Keywords
This publication has 48 references indexed in Scilit:
- Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With 131I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy ResultsJournal of Clinical Oncology, 2005
- Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisalExpert Review of Clinical Immunology, 2005
- The Radioisotope Contributes Significantly to the Activity of RadioimmunotherapyClinical Cancer Research, 2004
- Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with 90Y-biotin?Gynecologic Oncology, 2004
- Antibody-targeted radiation cancer therapyNature Reviews Drug Discovery, 2004
- Immunotherapy: past, present and futureNature Medicine, 2003
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2001
- Antibody-based therapies as anti-infective agentsExpert Opinion on Investigational Drugs, 1998
- Vehicles, Chelators, and Radionuclides: Choosing the “Building Blocks” of an Effective Therapeutic RadioimmunoconjugateBioconjugate Chemistry, 1996